TABLE 55Costs associated with PsA as a function of HAQ and PASI used in each of the models

Costs (£)
HAQPASI
Abbott151
By HAQ score:a

0.0 < 0.5 = 121 (59–173)

0.5 < 1.0 = 77 (43–109)

1.0 < 1.5 = 269 (141–382)

1.5 < 2.0 = 388 (206–550)

2.0 < 2.5 = 909 (459–1295)

2.5, 3.0 = 1945 (958–2778)
PASI state 1: score = 1.5 (1.5 to 2.7) = 153.68b

PASI state 2: score = 9 (7 to 11.2) = 933.62

PASI state 3: score = 15 (12.6 to 16.8) = 859.35

PASI state 4: score = 40 (32.4 to 43.2) = 1002.83
Schering-Plough152
Constant: mean = 1325, SE = 466

Slope: mean = 401, SE = 259
(CiC information has been removed)
Wyeth153
Does not present HAQ by score. Uses £2.05 per 3 months from sum of regression coefficients (also does this for SE). Cannot determine how this has been used in the model
a

Costs by HAQ score required for the model. Direct costs estimated by fitting an exponential line to the midpoint of each HAQ band.

b

For 6 months.

From: Appendix 8, Critique of the manufacturers' models

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.